Comparative efficacy of 2, 4 and 9valent vaccines on non 16 and 18 infection and diseases: evidences and questioning issues

• MSS 05-01 • Effectiveness issues: Vaccine efficacies against HPV cancers > M. Matti Lehtinen • MSS 05-02 • Efficacy issues: cervical See abstract > E. Elmar Joura • MSS 05-03 • Efficacy issues: non-cervical > X. Xavier Castellsagué • MSS 05-04 • Immunogenicity > S. Suzanne Garland • MSS 05-05 • IMMUNOGENICITY AND SAFETY OF THE 9-VALENT COMPARED TO THE 4-VALENT HPV VACCINE: RESULTS OF A DOUBLE-BLIND CONTROLLED STUDY IN 16-26 YEAR OLD MEN See abstract > P. Pierre Van Damme • MSS 05-07 • Alternative vaccination strategies See abstract > M. Miriam Elfström • MSS 05-08 • 2nd generation of vaccines, implications for screening See abstract > K. Karen Canfell • MSS 05-06 • REDUCED-DOSE SCHEDULES FOR PROPHYLACTIC HPV VACCINES See abstract > A. Aimée Kreimer